Key result
The mGlide randomized controlled trial is evaluating a mobile health intervention for hypertension control in 450 planned participants, with 107 patients randomized to date.
Why the study?
Suboptimal treatment of hypertension remains widespread, especially among minorities and socioeconomically disadvantaged groups, prompting evaluation of an mHealth-based partnership to improve control rates.
Does a 6-month mHealth intervention improve hypertension control rates in stroke survivors and primary care patients with elevated cardiovascular disease risk?
RCT (n=450)
Yes
Does a 6-month mHealth intervention improve hypertension control rates in stroke survivors and primary care patients with elevated cardiovascular disease risk?
This protocol outlines a randomized controlled trial to evaluate the effectiveness of a 6-month mHealth intervention for improving hypertension control in diverse, high-risk patient populations.
RCT protocol tests mHealth hypertension control in high-risk groups; leaves open efficacy until results emerge.
BACKGROUND Suboptimal treatment of hypertension remains a widespread problem, particularly among minorities and socioeconomically disadvantaged groups. We present a health system–based intervention with diverse patient populations using readily available smartphone technology. This intervention is designed to empower patients and create partnerships between patients and their provider team to promote hypertension control. OBJECTIVE The mGlide randomized controlled trial is a National Institutes of Health–funded study, evaluating whether a mobile health (mHealth)-based intervention that is an active partnership between interprofessional health care teams and patients results in better hypertension control rates than a state-of-clinical care comparison. METHODS We are recruiting 450 participants including stroke survivors and primary care patients with elevated cardiovascular disease risk from diverse health systems. These systems include an acute stroke service (n=100), an academic medical center (n=150), and community medical centers including Federally Qualified Health Centers serving low-income and minority (Latino, Hmong, African American, Somali) patients (n=200). The primary aim tests the clinical effectiveness of the 6-month mHealth intervention versus standard of care. Secondary aims evaluate sustained hypertension control rates at 12 months; describe provider experiences of system usability and satisfaction; examine patient experiences, including medication adherence and medication use self-efficacy, self-rated health and quality of life, and adverse event rates; and complete a cost-effectiveness analysis. RESULTS To date, we have randomized 107 participants (54 intervention, 53 control). CONCLUSIONS This study will provide evidence for whether a readily available mHealth care model is better than state-of-clinical care for bridging the guideline-to-practice gap in hypertension treatment in health systems serving diverse patient populations. CLINICALTRIAL Clinicaltrials.gov NCT03612271; https://clinicaltrials.gov/ct2/show/NCT03612271 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/25424
No takes yet. Share an insight, caveat, or question.
Lakshminarayan et al. (2020) conducted an RCT in Hypertension (n=450). mHealth-based intervention vs. Standard of care was evaluated on Hypertension control rates at 6 months. The mGlide randomized controlled trial is evaluating a mobile health intervention for hypertension control in 450 planned participants, with 107 patients randomized to date.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: